Author

Lucía Quintana‐Gallardo

Observed names: L., Quintana-Gallardo, Lucia Quintana-Gallardo, Lucía Quintana-Gallardo

Institution: Swedish Orphan Biovitrum (Sweden)

Observed institutions: Consejo Superior de Investigaciones Científicas, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, Centro Nacional de Biotecnología, Swedish Orphan Biovitrum (Sweden), Sarepta Therapeutics (United States)

ORCID: 0000-0002-1897-3535

Observed ORCID: 0000-0002-1897-3535

OpenAlex ID: A5020789765

Hsp70 – a master regulator in protein degradation

2017 · María Rosario Fernández‐Fernández, Marcos Gragera, et al. · FEBS Letters · 262

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations

2022 · Jerry R. Mendell, Anne M. Connolly, et al. · Molecular Therapy — Methods & Clinical Development · 130

The cochaperone CHIP marks Hsp70- and Hsp90-bound substrates for degradation through a very flexible mechanism

2019 · Lucía Quintana-Gallardo, Jaime Martín-Benito, et al. · Scientific Reports · 74

Macrophage-specific MHCII expression is regulated by a remote Ciita enhancer controlled by NFAT5

2018 · Maria Buxadé, Hector Huerga Encabo, et al. · The Journal of Experimental Medicine · 68

Modulation of the Chaperone DnaK Allosterism by the Nucleotide Exchange Factor GrpE

2015 · Roberto Melero, Fernando Moro, et al. · Journal of Biological Chemistry · 26

Clinical Presentation, Treatment Patterns, Burden of Disease, and the Association of Proteinuria with Clinical Outcomes in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis: A Systematic Review

2025 · Fernando Caravaca-Fontán, Fadi Fakhouri, et al. · The Nephron journals/Nephron journals · 3

Combining Electron Microscopy (EM) and Cross-Linking Mass Spectrometry (XL-MS) for Structural Characterization of Protein Complexes

2021 · Lucía Quintana-Gallardo, Moisés Maestro-López, et al. · Methods in molecular biology · 3

‘…completely exhausted and weak, really drained.’: a multinational qualitative interview study of healthcare provider, patient, and caregiver experiences of C3 glomerulopathy and primary (idiopathic) immune complex membranoproliferative glomerulonephritis diagnosis, burden and management

2026 · Sayna Norouzi, Mingyi Huang, et al. · Frontiers in Nephrology

Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative GN

2025 · Fernando Caravaca-Fontan, Sayna Norouzi, et al. · Kidney360

Wcn24-683 Efficacy of 12-week Pegcetacoplan in Kidney Transplant Recipients With Recurrent C3 Glomerulopathy (c3g) or Immune Complex Membranoproliferative Glomerulonephritis (ic-mpgn)

2024 · Lucia Quintana-Gallardo, Andrew Bomback, et al. · Kidney International Reports

Works count: 11

Citation count: 566

H-index: 5

I10-index: 5